Hepatitis B Seroprevalence among Petrochemical Workers: Workplace Versus Community Baseline in Nigeria

Objectives: Hepatitis B virus (HBV) remains hyperendemic in Nigeria, with national HBsAg seroprevalence estimated at 8.1% among adults aged 15–64 years. Petrochemical workers face occupational blood-exposure risks through industrial injuries, yet facility-specific baseline data are scarce. This study aimed to establish facility-specific baseline seroprevalence among petrochemical workers, test the validity of community-extrapolation assumptions in occupational health policy, and examine plausible mechanisms for any observed divergence between workplace and community rates. Methods: We conducted a cross-sectional screening of 184 consecutive petrochemical workers undergoing mandatory periodic fitness-to-work evaluation at three operational locations in Nigeria between November 2018 and April 2019. HBsAg was detected using a rapid immunochromatographic assay (sensitivity ≥99.0%, specificity ≥99.0%). Prevalence was calculated with exact binomial 95% confidence intervals. Prevalence ratios and approximate 95% CIs were computed using the delta method on the log scale against community baselines. Fisher exact test was used for categorical associations. Results: The cohort comprised 178 males (96.7%) and 6 females (3.3%), with mean age 43.9 ± 5.4 years. One worker tested HBsAg-positive, yielding a prevalence of 0.54% (exact 95% CI: 0.01–2.99%). Compared with the Nigeria NAIIS 2018 baseline, the prevalence ratio was 0.07 (95% CI: 0.01–0.43), p < 0.001. Compared with the pooled Nigerian meta-analytic estimate, the prevalence ratio was 0.06 (95% CI: 0.01–0.40), p < 0.001. Neither community baseline confidence interval overlapped with the workplace estimate. Sensitivity analysis confirmed robustness: even with five positive cases, prevalence remained below the national lower bound. Conclusions: A 0.54% seroprevalence—approximately 15-fold below the national baseline—demands mechanistic explanation rather than celebration. Pre-employment screening, vaccination coverage, and workforce selection effects are plausible, non-mutually-exclusive drivers. Facility-specific seroprevalence monitoring, vaccination audits, and hiring-screening transparency are required before low workplace rates can be interpreted as prevention success.

Hepatitis B virus; Occupational exposure; Petrochemical industry; Seroepidemiology; Nigeria

1. Sheena, B.S., Hiebert, L., Han, H., et al. (2022). Global, regional, and national burden of hepatitis B, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterology and Hepatology, 7(9), 796-829. https://doi.org/10.1016/S2468-1253(22)00124-8 [Google Scholar] [Crossref]

2. National Population Commission and ICF (2019). Nigeria AIDS Indicator and Impact Survey (NAIIS) 2018: Summary Sheet — Preliminary Findings. Abuja, Nigeria, and Rockville, Maryland, USA: NPC and ICF. [Google Scholar] [Crossref]

3. Olakunde, B.O. (2025). Epidemiology of Hepatitis B virus infection in Nigeria. International Journal of Infectious Diseases, [Epub ahead of print]. https://doi.org/10.1016/j.ijid.2025.01.008 [Google Scholar] [Crossref]

4. Ajuwon, B.I., Yujuico, I., Roper, K., Richardson, A., Sheel, M. and Lidbury, B.A. (2021). Hepatitis B virus infection in Nigeria: A systematic review and meta-analysis of data published between 2010 and 2019. BMC Infectious Diseases, 21(1), 1120. https://doi.org/10.1186/s12879-021-06800-6 [Google Scholar] [Crossref]

5. World Health Organization (2024). Global Hepatitis Report 2024. Geneva: WHO. [Google Scholar] [Crossref]

6. Shrivastava, R.K. and Chaurasia, D. (2025). Evaluation of rapid diagnostic test compared with ELISA for detection of hepatitis B surface antigen. International Journal of Medical Reviews, 7(2), 189-193. [Google Scholar] [Crossref]

7. Federal Republic of Nigeria (2019). Discrimination Against Persons with Disabilities (Prohibition) Act, 2018. Signed into law 23 January 2019. Official Gazette of the Federal Republic of Nigeria, 106(24). [Google Scholar] [Crossref]

8. Orji, C.J., Chime, O.H. and Ndibuagu, E.O. (2020). Vaccination status and prevalence of hepatitis B virus infection among health-care workers in a tertiary health institution, Enugu State, Nigeria. Proceedings of Singapore Healthcare, 29(2), 119-125. https://doi.org/10.1177/2010105820923892 [Google Scholar] [Crossref]

9. Adegbamigbe, O.J., Yusuf, M., Durowade, K.A., Oguntoye, O.O. and Ogundare, Y. (2022). Exposure to patients' sample and prevalence of hepatitis B and C virus infection among health-care workers in a Nigerian tertiary hospital. Annals of African Medicine, 21(4), 322-326. https://doi.org/10.4103/aam.aam_28_21 [Google Scholar] [Crossref]

10. Ijoma, U.N., Meka, I.A., Omotowo, B., et al. (2021). Sero-prevalence of hepatitis B virus infection: A cross-sectional study of a large population of health care workers in Nigeria. Nigerian Journal of Clinical Practice, 24(1), 38-44. https://doi.org/10.4103/njcp.njcp_207_20 [Google Scholar] [Crossref]

11. Hiebert-Suwondo, L., Manning, J., Tohme, R.A., et al. (2025). A 2024 global report on national policies, programmes, and progress towards hepatitis B elimination. Lancet Gastroenterology and Hepatology, 10(5), e20-e30. https://doi.org/10.1016/S2468-1253(25)00068-8 [Google Scholar] [Crossref]

12. World Health Organization (2024). Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: WHO. [Google Scholar] [Crossref]

13. Ya'aba, Y., Mohammed, S.B., Olatunji, K.T., et al. (2019). Hepatitis B and C virus among health care workers in National Institute for Pharmaceutical Research and Development (NIPRD). Iranian Journal of Health Safety and Environment, 5(3), 373-382. [Google Scholar] [Crossref]

14. Yakubu, Y., Mojisola, O. and Ismaila, A.M. (2023). Seroprevalence and knowledge of hepatitis B and C among healthcare workers in three healthcare centers in Nasarawa State, Nigeria. Research Square. https://doi.org/10.21203/rs.3.rs-3069564/v1 [Google Scholar] [Crossref]

• Chayomed: Pharmacotheraputic Potential of Chayote (Sechium Edule) Peel Extract on Diabetes Mellitus and its Cancer Chemoprevention Property
• Phytonutraceutical Value of Buro Bitoon: A Cancer Chemopreventive and Anti-Inflammatory Agent
• Environmental Constraints on Setaria Italica Cultivation in Western Rajasthan: A Comprehensive Review